Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.61 |
| ▸ | GSK3B | P49841 | 12/20 | 0.56 |
| ▸ | F11 | P03951 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240358 | 1.00 | ULK1 (0.61) | ULK1GSK3BF11PIK3C3JAK2 | |
| SCHEMBL26686340 | 0.86 | JAK2 (0.56) | ULK1F11JAK2 | |
| SCHEMBL31420125 | 0.85 | DYRK1A (0.51) | JAK2 | |
| SCHEMBL26685950 | 0.85 | DYRK1A (0.51) | JAK2 | |
| SCHEMBL26686055 | 0.84 | DYRK1A (0.52) | — | |
| SCHEMBL30633289 | 0.84 | DYRK1A (0.52) | — | |
| SCHEMBL31420111 | 0.83 | F11 (0.46) | ULK1GSK3BF11JAK2 | |
| SCHEMBL26685887 | 0.83 | F11 (0.46) | ULK1GSK3BF11JAK2 | |
| SCHEMBL31420540 | 0.82 | GSK3B (0.52) | GSK3BPIK3C3 | |
| SCHEMBL26686188 | 0.82 | GSK3B (0.52) | GSK3BPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | ULK1 952/4885GSK3B 73/4885F11 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.